SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Product › Details


Products Next higher product group budesonide (INN)
Period Status 2018-10-19 development p3 start
Organisation Organisation Marinomed Biotech AG (VSE: MARI)

Marinomed Biotech AG. (10/19/18). "Press Release: Initiation of First Marinosolv Clinical Trial (Ph III)".

Marinomed Biotech AG is proud to announce the initiation of their Ph III clinical trial “BDS_18_01” with their first Marinosolv-based investigational medicinal product, “Budesolv 10 micrograms, nasal spray”. This nasal spray will be the first budesonide-based treatment for allergic rhinitis (hay fever) that delivers the active substance in dissolved form, thereby allowing treatment with a lower dose of budesonide than marketed products in a preservative-free configuration. The patent-protected development product will be tested for the indication of allergic rhinitis in the setting of the clinical research facility VCC (Vienna Challenge Chamber), the first and world-leading study center that performs clinical allergy trials under controlled and reproducible conditions in Vienna (

[Photo] The “Budesolv 10” study team during the initiation visit at the Vienna Challenge Chamber. Left to right: Dr. Reinhard Riedlsperger, Mag. Martina Görner, CRS Riedlsperger GmbH; Dr. Patrick Lemell, Dr. Petra Zieglmayer, Ing. Rene Zieglmayer, Vienna Challenge Chamber; Dr. Nicole Unger-Manhart, Dr. Eva Prieschl-Grassauer, Dr. Andreas Goessl, Mag. Sabine Grohmann, Marinomed Biotech AG

Record changed: 2019-04-26


Picture [LSUS] – The Business Web Portal 600x60px

More documents for budesonide (INN)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 600x60px

» top